Created at Source Raw Value Validated value
June 25, 2024, noon usa

* history of anaphylactic response to vaccine components. * acute febrile illness. * guillain-barré syndrome, decompensated heart failure (class iii or iv), demyelinating disease. * history of live virus vaccine up to 4 weeks before, virus vaccine inactivated up to 2 weeks before. * history of having received blood products up to 6 months before the study. * individuals who do not accept to participate in the study and/or whose guardians do not agree to participate in the study. * hospitalized patients. * patients with severe conditions requiring hospitalization.

* history of anaphylactic response to vaccine components. * acute febrile illness. * guillain-barré syndrome, decompensated heart failure (class iii or iv), demyelinating disease. * history of live virus vaccine up to 4 weeks before, virus vaccine inactivated up to 2 weeks before. * history of having received blood products up to 6 months before the study. * individuals who do not accept to participate in the study and/or whose guardians do not agree to participate in the study. * hospitalized patients. * patients with severe conditions requiring hospitalization.

Feb. 17, 2021, 12:31 a.m. usa

- history of anaphylactic response to vaccine components. - acute febrile illness. - guillain-barré syndrome, decompensated heart failure (class iii or iv), demyelinating disease. - history of live virus vaccine up to 4 weeks before, virus vaccine inactivated up to 2 weeks before. - history of having received blood products up to 6 months before the study. - individuals who do not accept to participate in the study and/or whose guardians do not agree to participate in the study. - hospitalized patients. - patients with severe conditions requiring hospitalization.

- history of anaphylactic response to vaccine components. - acute febrile illness. - guillain-barré syndrome, decompensated heart failure (class iii or iv), demyelinating disease. - history of live virus vaccine up to 4 weeks before, virus vaccine inactivated up to 2 weeks before. - history of having received blood products up to 6 months before the study. - individuals who do not accept to participate in the study and/or whose guardians do not agree to participate in the study. - hospitalized patients. - patients with severe conditions requiring hospitalization.